Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risk of Bleeding With Dabigatran in Atrial Fibrillation JAMA Intern Med. 2015;175(1): doi: /jamainternmed Association Among Bleeding Events, Treatment, and Patient CharacteristicsThe hazard ratios (HRs) were estimated by Cox proportional hazards regression models with propensity score weighting. The number of other comorbidities has been calculated as the sum of previous history of acute myocardial infarction, Alzheimer disease, related disorders or senile dementia, anemia, asthma, benign prostatic hyperplasia, cataract, chronic obstructive pulmonary disease, congestive heart failure, depression, diabetes mellitus, ischemic heart disease, hip or pelvic fracture, glaucoma, hyperlipidemia, osteoporosis, rheumatoid arthritis or osteoarthritis, breast cancer, colorectal cancer, prostate cancer, lung cancer, and endometrial cancer. Nonsteroidal anti-inflammatory drugs (NSAIDs) include diclofenac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, piroxicam, meloxicam, mefenamic acid, and indomethacin. Antiplatelet agents include aspirin, clopidogrel, prasugrel, dipyridamol, ticlopidine, and ticagrelor. The concurrent risk score was calculated with the use of an algorithm as described in the text; higher scores predict greater medical spending. CMS indicates Centers for Medicare & Medicaid Services; TIA, transient ischemic attack. Error bars indicate 95% CIs. Figure Legend:

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risk of Bleeding With Dabigatran in Atrial Fibrillation JAMA Intern Med. 2015;175(1): doi: /jamainternmed Hazard Ratios (HRs) for Bleeding Events by Anatomical Site and TreatmentThe HRs were estimated by Cox proportional hazards regression models with propensity score weighting that controlled for age, sex, race, chronic kidney disease, history of stroke or transient ischemic attack, hypertension, acquired hypothyroidism, history of bleeding in the year before treatment initiation, history of hospitalization in the year before treatment initiation, use of nonsteroidal anti-inflammatory drugs, use of antiplatelet agents, number of other Centers for Medicare & Medicaid Services priority comorbidities, and annual concurrent risk score. NOS indicates not otherwise specified. Error bars indicate 95% CIs. Figure Legend:

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risk of Bleeding With Dabigatran in Atrial Fibrillation JAMA Intern Med. 2015;175(1): doi: /jamainternmed Hazard Ratios (HRs) for Bleeding Events by Anatomical Site, Subgroup, and TreatmentThe HRs were estimated by Cox proportional hazards regression models with propensity score weighting. The general model controlled for age, sex, race, chronic kidney disease (CKD), history of stroke or transient ischemic attack, hypertension, acquired hypothyroidism, number of other Centers for Medicare & Medicaid Services (CMS) priority comorbidities, history of bleeding in the year before treatment initiation, history of hospitalization in the year before treatment initiation, use of nonsteroidal anti-inflammatory drugs, use of antiplatelet agents, and annual concurrent risk score. Subgroup analyses controlled for the same covariates except for the one defining the subgroup. For example, age-stratified analysis controlled for the same covariates except for age. The number of comorbidities used to define the subgroup with 7 or more comorbidities was calculated as the sum of all CMS priority comorbidities but atrial fibrillation (previous history of acute myocardial infarction, Alzheimer disease, related disorders or senile dementia, anemia, asthma, benign prostatic hyperplasia, cataract, chronic obstructive pulmonary disease, congestive heart failure, depression, diabetes mellitus, ischemic heart disease, hip or pelvic fracture, glaucoma, hyperlipidemia, osteoporosis, rheumatoid arthritis or osteoarthritis, breast cancer, colorectal cancer, prostate cancer, lung cancer and endometrial cancer, history of stroke or transient ischemic attack, hypertension, acquired hypothyroidism, and CKD). Error bars indicate 95% CIs. Figure Legend: